IKT
Inhibikase Therapeutics Inc
NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY
$1.86
-1.76% today
Updated 2026-06-03
Market cap
$268.03M
P/E ratio
—
P/S ratio
10.39x
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $2
Volume
0.8M
Inhibikase Therapeutics Inc (IKT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $162927.00 | $285167.00 | $2.85M | $38254.00 | $14.78M | $42.47M | $24.94M | $14.51M | $98.60M | $181.20M |
| Cash & equivalents | $12036.00 | $16665.00 | $379557.00 | $18457.00 | $13.95M | $40.75M | $7.19M | $9.17M | $56.49M | $139.22M |
| Current assets | $80164.00 | $198070.00 | $1.25M | $35381.00 | $14.78M | $42.47M | $24.37M | $14.21M | $98.45M | $180.11M |
| Total liabilities | $1.51M | $1.73M | $3.62M | $4.53M | $5.00M | $4.05M | $3.90M | $3.53M | $3.73M | $8.30M |
| Current liabilities | $1.51M | $1.73M | $3.62M | $4.25M | $4.72M | $4.05M | $3.70M | $3.44M | $3.73M | $8.30M |
| Long-term debt | — | — | — | $275375.00 | $276461.00 | — | — | — | — | — |
| Shareholder equity | $-1.35M | $-1.44M | $-777965.00 | $-4.49M | $9.78M | $38.42M | $21.04M | $10.98M | $94.87M | $172.90M |
| Retained earnings | $-3.87M | $-4.31M | $-6.46M | $-12.18M | $-15.03M | $-29.82M | $-47.87M | $-66.90M | $-94.42M | $-142.68M |
| Accounts receivable | $66878.00 | $180780.00 | $472941.00 | — | $0.00 | $110141.00 | $39881.00 | $39881.00 | — | — |
| Inventory | $0.00 | — | — | — | — | $107000.00 | $1.12M | $1.12M | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |
Frequently asked questions
What is Inhibikase Therapeutics Inc's revenue?
Inhibikase Therapeutics Inc's trailing twelve-month revenue is $1.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does IKT generate?
IKT produced $-27.80M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IKT's balance sheet healthy?
IKT holds $139.22M in cash and equivalents against — in long-term debt, on $172.90M of shareholder equity. That debt is best read against the cash flow the business throws off each year.